The University of Chicago Header Logo

Connection

Mark Kozloff to Caspase 3

Back to Details
This is a "connection" page, showing publications Mark Kozloff has written about Caspase 3.
Mark Kozloff
Connection Strength
0.028
Caspase 3
  1. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer. 2013 Dec 15; 119(24):4290-8.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.